BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Impressive Q2 CY2026, Full
BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2026 results. Revenue rose 19.9% year over year to $989.7 million and exceeded analysts’ estimates by 6.5%. Full-year revenue guidance was $3.9 billion at the midpoint, 0.7% above estimates. Non-GAAP adjusted EPS was $1.20, 26.6% above consensus. The stock rose 3.7% to $63.75.
How this was made
The 30-second read
Why it matters
Traders can use the reported beat and guidance versus consensus to reassess near-term expectations, while monitoring margin compression and YoY EPS decline as potential headwinds.
Market read
A concrete earnings and guidance beat with a noted margin contraction creates a tradable setup for post-earnings positioning in US biotech.
What to watch
The article cites integration of Amicus and growth plans for GALAFOLD and POMBILITI plus OPFOLDA, but provides no quantified milestones for those programs, leaving execution risk underappreciated.
Background
BioMarin’s Q2 CY2026 update includes revenue and EPS beats, full-year revenue guidance at the midpoint, and commentary on integrating Amicus and advancing growth plans for key therapies.
Ticker impact
BioMarin reported Q2 CY2026 revenue of $989.7M (+19.9% YoY) and non-GAAP EPS $1.20, beating estimates and reiterating full-year revenue guidance.
Likely supports continued post-earnings bid, though margin contraction and YoY EPS decline may cap upside.
The article provides concrete beats versus estimates and a small guidance outperformance, but also highlights adjusted operating margin down YoY and adjusted EPS down YoY, creating a mixed fundamental read-through.
Market effects
Biotech large-cap earnings beat with growth and integration narrative may modestly support sentiment toward rare-disease commercial models.
Primarily US biotech sentiment; limited direct regional spillover beyond NASDAQ/US healthcare tape.
Rare genetic disorder treatment demand and integration execution are globally relevant, but the article is US-focused and lacks international-specific disclosures.
Counterpoint
Despite the beat, adjusted EPS fell YoY and operating margin contracted, suggesting the quality of earnings may be less durable than revenue growth implies.
Key entities
- companyBioMarin Pharmaceutical
Reported Q2 CY2026 revenue and non-GAAP EPS, provided full-year revenue guidance, and discussed integration and growth plans.
- companyAmicus
BioMarin is integrating Amicus into its operations, per CEO commentary.
- productGALAFOLD
BioMarin cited plans to accelerate growth for GALAFOLD.
- productPOMBILITI and OPFOLDA
BioMarin cited plans to accelerate growth and extend benefits to more patients worldwide.
